摘要
滤泡性淋巴瘤发病率居非霍奇金淋巴瘤第2位,因其缓解后易复发,给临床治疗带来极大困难。2017年9月,FDA加速批准磷脂酰肌醇3-激酶抑制剂(PI3K抑制剂)copanlisib上市,用于至少接受过两次全身治疗的成人复发性滤泡性淋巴瘤。临床研究显示,copanlisib有较好的客观缓解率。本文就其药理作用、临床评价、安全性及用法用量等做一综述。
The morbidity of follicular lymphoma（FL） is second in non-Hodgkin＇s lymphoma（NHL）. FL is easy to relapse after remission, being very difficult to control. It was preferentially approved as a PI3 K inhibition for the treatment of relapsed FL in adult patients receiving at least two prior therapies by FDA in September 2017. Good objective remission rate was obtained in clinical studies. The pharmacological actions, clinical evaluation, safety, dosage and administration were reviewed in this paper.
出处
《临床药物治疗杂志》
2018年第1期27-31,共5页
Clinical Medication Journal
